Adicet Bio 10-Q 6 Nov 15 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2015	Nov. 02, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	ACETO CORP
Entity Central Index Key	2,034
Trading Symbol	acet
Current Fiscal Year End Date	--06-30
Entity Filer Category	Accelerated Filer
Entity Common Stock Shares Outstanding		29,502,043
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 30,830	$ 34,020
Investments	2,392	3,416
Trade receivables, less allowance for doubtful accounts (September 30, 2015, $690; June 30, 2015, $691)	167,925	161,521
Other receivables	10,102	10,611
Inventory	90,302	95,596
Prepaid expenses and other current assets	4,267	3,096
Deferred income tax asset, net	1,581	2,050
Total current assets	307,399	310,310
Property and equipment, net	10,357	10,456
Property held for sale	6,574	6,574
Goodwill	67,883	67,870
Intangible assets, net	82,745	78,997
Deferred income tax asset, net	9,946	9,972
Other assets	5,742	5,595
TOTAL ASSETS	490,646	489,774
Current liabilities:
Current portion of long-term debt	197	10,197
Accounts payable	49,280	54,962
Accrued expenses	55,683	59,841
Total current liabilities	105,160	125,000
Long-term debt	109,911	99,960
Long-term liabilities	7,690	7,542
Environmental remediation liability	2,678	2,995
Deferred income tax liability	32	66
Total liabilities	$ 225,471	$ 235,563
Commitments and contingencies (Note 6)
Shareholders' equity:
Preferred stock, 2,000 shares authorized; no shares issued and outstanding
Common stock, $.01 par value, 40,000 shares authorized; 29,488 and 29,147 shares issued and outstanding at September 30, 2015 and June 30, 2015, respectively	$ 295	$ 292
Capital in excess of par value	96,314	93,807
Retained earnings	174,745	167,208
Accumulated other comprehensive loss	(6,179)	(7,096)
Total shareholders' equity	265,175	254,211
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 490,646	$ 489,774

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Statement Of Financial Position [Abstract]
Trade receivables, allowance for doubtful accounts (in dollars)	$ 690	$ 691
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	40,000	40,000
Common stock, shares issued	29,488	29,147
Common stock, shares outstanding	29,488	29,147

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net sales	$ 133,500	$ 130,803
Cost of sales	98,919	103,152
Gross profit	34,581	27,651
Selling, general and administrative expenses	17,633	18,283
Research and development expenses	1,430	745
Operating income	15,518	8,623
Other (expense) income:
Interest expense	(754)	(1,036)
Interest and other income, net	219	58
Other (expense) income, Total	(535)	(978)
Income before income taxes	14,983	7,645
Provision for Income taxes	5,685	2,817
Net income	$ 9,298	$ 4,828
Basic income per common share (in dollars per share)	$ 0.32	$ 0.17
Diluted income per common share (in dollars per share)	$ 0.32	$ 0.17
Weighted average shares outstanding:
Basic (in shares)	28,983	28,618
Diluted (in shares)	29,392	29,178

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive (loss) Income [Abstract]
Net income	$ 9,298	$ 4,828
Other comprehensive income:
Foreign currency translation adjustments	1,066	(4,475)
Change in fair value of interest rate swaps	(149)	252
Comprehensive income	$ 10,215	$ 605

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities:
Net income	$ 9,298	$ 4,828
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	3,089	3,029
Provision for doubtful accounts	25	166
Non-cash stock compensation	1,467	1,129
Deferred income taxes	477	(40)
Earnings on equity investment in joint venture	(109)	(456)
Changes in assets and liabilities:
Trade accounts receivable	(6,126)	(5,894)
Other receivables	1,051	320
Inventory	5,607	6,546
Prepaid expenses and other current assets	(1,153)	(1,351)
Other assets	106	490
Accounts payable	(5,821)	(4,357)
Accrued expenses and other liabilities	(4,937)	(5,309)
Net cash provided by (used in) operating activities	2,974	(899)
Investing activities:
Purchases of investments	(16)	(1,083)
Sales of investments	1,006
Payments for intangible assets	(6,450)	(921)
Purchases of property and equipment, net	(312)	(225)
Net cash used in investing activities	(5,772)	(2,229)
Financing activities:
Payment of cash dividends		(1,741)
Proceeds from exercise of stock options	115	844
Excess tax benefit on stock option exercises and restricted stock	820	513
Payment of contingent consideration	(1,500)
Borrowings of bank loans	10,500	5,000
Repayment of bank loans	(10,549)	(2,196)
Net cash (used in) provided by financing activities	(614)	2,420
Effect of exchange rate changes on cash	222	(1,520)
Net decrease in cash	(3,190)	(2,228)
Cash and cash equivalents at beginning of period	34,020	42,897
Cash and cash equivalents at end of period	30,830	$ 40,669
Non-Cash Item
Dividends declared but unpaid	$ 1,745

Basis of Presentation

Basis of Presentation	3 Months Ended
	Sep. 30, 2015
Basis Of Presentation [Abstract]
Basis of Presentation	( 1) Basis of Presentation The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; and stock-based compensation. These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Form 10-K for the year ended June 30, 2015.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	(2) Stock-Based Compensation At the annual meeting of shareholders of the Company, held on December 6, 2012, the Company’s shareholders approved the amended and restated Aceto Corporation 2010 Equity Participation Plan (the “2010 Plan”). Under the 2010 Plan, grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses (collectively, “Stock Awards”) may be made to employees, non-employee directors and consultants of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time. During the three months ended September 30, 2015, the Company granted 208 shares of restricted common stock to its employees that vest over three years and 46 restricted stock units that have varying vest dates through August 2016. In addition, the Company also issued a target grant of 142 performance-vested restricted stock units, which grant could be as much as 248 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant. During the year ended June 30, 2015, the Company granted 165 shares of restricted common stock to its employees that vest over three years and 12 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 67 restricted stock units that have varying vest dates through August 2016. In addition, the Company also issued a target grant of 116 performance-vested restricted stock units, which grant could be as much as 203 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant. For the three months ended September 30, 2015 and 2014, the Company recorded stock-based compensation expense of approximately $1,462 and $1,103, respectively, related to restricted common stock and restricted stock units. As of September 30, 2015, the total unrecognized compensation cost related to restricted stock awards and units is approximately $12,531.

Common Stock

Common Stock	3 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Common Stock	(3) Common Stock On September 10, 2015, the Company's board of directors declared a regular quarterly dividend of $0.06 per share which was paid on October 2, 2015 to shareholders of record as of September 21, 2015. On May 8, 2014, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2017. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase. The Board of Directors has authority under the Company’s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.

Net Income Per Common Share

Net Income Per Common Share	3 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Net Income Per Common Share	(4) Net Income Per Common Share Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding: Three months ended 2015 2014 Weighted average shares outstanding 28,983 28,618 Dilutive effect of stock options and restricted stock awards and units 409 560 Diluted weighted average shares outstanding 29,392 29,178

Debt

Debt	3 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt	(5) Debt Long-term debt September 30, 2015 June 30, 2015 Revolving bank loans $ 47,500 $ 45,000 Term bank loans 59,500 62,000 Mortgage 3,108 3,157 110,108 110,157 Less current portion 197 10,197 $ 109,911 $ 99,960 Credit Facilities On April 30, 2014, and in connection with the purchase of PACK Pharmaceuticals, LLC (“PACK”), Aceto entered into a new Credit Agreement (the “Credit Agreement”) with three domestic financial institutions. The Credit Agreement terminated the Credit Agreement, dated December 31, 2010. On June 25, 2015, Aceto entered into Amendment No. 1 to its Credit Agreement dated April 30, 2014 (together with the Credit Agreement, the “Amended Credit Agreement”). The Amended Credit Agreement increased the aggregate revolving commitment (the “Revolving Commitment”) under the existing credit facility from $60,000 to $75,000. Aceto may borrow, repay and reborrow during the period ending April 30, 2019, up to but not exceeding at any one time outstanding $75,000 under the Revolving Commitment. The Revolving Commitment provides for (i) Eurodollar Loans (as such terms are defined in the Amended Credit Agreement), (ii) ABR Loans (as such terms are defined in the Amended Credit Agreement) or (iii) a combination thereof. As of September 30, 2015, the Company borrowed Revolving Loans aggregating $47,500 which loans are Eurodollar Loans at interest rates ranging from 1.96% to 2.41% at September 30, 2015. The Amended Credit Agreement also allows for the borrowing of up to $70,000 (the “Term Commitment”). The Term Commitment interest may be payable as (i) a Eurodollar Loan, (ii) an ABR Loan, or (iii) a combination thereof. The Company borrowed a Term Loan of $70,000 on April 30, 2014 to partially finance the acquisition of PACK. As of September 30, 2015, the remaining amount outstanding under the amortizing Term Loan is $59,500 and is payable as a Eurodollar Loan at an interest rate of 2.08% at September 30, 2015. Proceeds of the Term Commitment and a portion of the proceeds of the Revolving Commitment were used to fund the initial cash consideration for PACK and to repay the outstanding balance of term loans from the Credit Agreement dated December 31, 2010. The Amended Credit Agreement also provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services by us in the ordinary course of business. The Company had open letters of credit of approximately $21 at September 30, 2015 and June 30, 2015 respectively. The terms of these letters of credit are all less than one year. No material loss is anticipated due to non-performance by the counterparties to these agreements. The Amended Credit Agreement provides for a security interest in all of our personal property. The Amended Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service. The Company is also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, sale of assets, sales of receivables, and loans and investments. The Company was in compliance with all covenants at September 30, 2015. Subsequent to September 30, 2015, the Company amended its Amended Credit Agreement (see Note 10). Mortgage On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its new corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013, bears interest at 4.92% per annum as of September 30, 2015 and matures on June 30, 2021.

Commitments, Contingencies and

Commitments, Contingencies and Other Matters	3 Months Ended
	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments, Contingencies and Other Matters	(6) Commitments, Contingencies and Other Matters The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what is discussed below, because the amount of the liability cannot be reasonably estimated at this time. In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State has begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity. The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $16,500 and $18,300. Remediation commenced in fiscal 2010, and as of September 30, 2015 and June 30, 2015, a liability of $10,761 and $11,079, respectively, is included in the accompanying consolidated balance sheets for this matter. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period. In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of September 30, 2015 and June 30, 2015 is $4,842 and $4,985, respectively, which is included in the accompanying consolidated balance sheets. In March 2006, Arsynco received notice from the United States Environmental Protection Agency (“EPA”) of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owner of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known. A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $2,160 through fiscal 2016, of which $0 has been accrued as of September 30, 2015 and June 30, 2015 respectively. On April 30, 2014, Rising, a wholly owned subsidiary of Aceto, acquired 100% of the issued and outstanding membership interests of PACK. PACK, a national marketer and distributor of generic prescription and over-the-counter pharmaceutical products, had headquarters in Buffalo Grove, Illinois, a suburb of Chicago, Illinois. The purchase agreement provided for a three-year earn-out of up to $15,000 in cash based on the achievement of certain performance-based targets. As of September 30, 2015 and June 30, 2015, the Company accrued $808 and $783, respectively, related to this contingent consideration. Any necessary future adjustments to this amount will be recorded as an income statement charge at that time.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	(7) Fair Value Measurements GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s assumptions (unobservable inputs). The hierarchy consists of three levels: Level 1 – Quoted market prices in active markets for identical assets or liabilities; Level 2 – Inputs other than Level 1 inputs that are either directly or indirectly observable; and Level 3 – Unobservable inputs that are not corroborated by market data. On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Aceto’s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At September 30, 2015, the Company had foreign currency contracts outstanding that had a notional amount of $53,203. Unrealized losses on hedging activities for the three months ended September 30, 2015 and 2014 was $251 and $806, In conjunction with the Credit Agreement, the Company entered into an interest rate swap on April 30, 2014 for an additional interest cost of 1.63% on a notional amount of $25,750, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is April 30, 2019. The notional balance of this derivative as of September 30, 2015 is $29,000. Pursuant to the requirements of the Credit Agreement, dated December 31, 2010, the Company was required to deliver Hedging Agreements (as defined in the agreement) fixing the interest rate on not less than $20,000 of the term loan at that time. Accordingly, in March 2011, the Company entered into an interest rate swap for an additional interest cost of 1.91% on a notional amount of $20,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 31, 2015. The notional amount of this derivative as of September 30, 2015 is $750. The unrealized loss to date associated with these two derivatives, which is recorded in accumulated other comprehensive income in the consolidated balance sheet at September 30, 2015, is $487. Aceto’s interest rate swaps are classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates. As of September 30, 2015 and June 30, 2015, the Company had $808 and $783, respectively, of contingent consideration related to the PACK acquisition, which was completed in April 2014 and $371 and $359, respectively, of contingent consideration related to the acquisition of a company in France, which occurred in December 2013. In addition, as of June 30, 2015, the Company had $1,480, of contingent consideration that was recorded at fair value in the Level 3 category, which related to the acquisition of Rising that was completed during fiscal 2011. The Rising contingent consideration was paid in September 2015. The contingent consideration was calculated using the present value of a probability weighted income approach. During the fourth quarter of each fiscal year, the Company evaluates goodwill and indefinite-lived intangibles for impairment at the reporting unit level using a cash flow model using Level 3 inputs. Additionally, on a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment. Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value. Measurements based on undiscounted cash flows are considered to be Level 3 inputs. The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at September 30, 2015 and June 30, 2015: Fair Value Measurements at September 30, 2015 Using Quoted Prices Significant Significant Total Cash equivalents: Time deposits - $ 6,383 - $ 6,383 Investments: Time deposits - 2,392 - 2,392 Foreign currency contracts- assets (1) - 183 - 183 Foreign currency contracts-liabilities (2) - 438 - 438 Derivative liability for interest rate swap (3) - 487 - 487 Contingent consideration (4) - - $ 1,179 1,179 (1) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015. (2) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015. (3) $3 included in “Accrued expenses” and $484 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015. (4) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015. Fair Value Measurements at June 30, 2015 Using Quoted Prices Significant Significant Total Cash equivalents: Time deposits - $ 6,376 - $ 6,376 Investments: Time deposits - 3,416 - 3,416 Foreign currency contracts-assets (5) - 119 - 119 Foreign currency contracts-liabilities (6) - 767 - 767 Derivative liability for interest rate swap (7) - 338 - 338 Contingent consideration (8) - - $ 2,622 2,622 (5) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2015. (6) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2015. (7) $13 included in “Accrued expenses” and $325 included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2015. (8) $1,480 included in “Accrued expenses” and $1,142 included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2015. The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Sep. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	(8) Recent Accounting Pronouncements In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, Business Combinations (Topic 805); Simplifying the Accounting for Measurement-Period Adjustments. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) Simplifying the Measurement of Inventory. In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Interest—Imputation of Interest (Subtopic 835-30) Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40) In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606),

Segment Information

Segment Information	3 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Information	(9) Segment Information The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals. Human Health Pharmaceutical Ingredients Performance Chemicals Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth. The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment. Three Months Ended September 30, 2015 and 2014: Human Health Pharmaceutical Ingredients Performance Unallocated Corporate Consolidated Totals 2015 Net sales $ 57,481 $ 38,360 $ 37,659 $ - $ 133,500 Gross profit 20,309 6,114 8,158 - 34,581 Income (loss) before income taxes 10,503 2,099 3,544 (1,163 ) 14,983 2014 Net sales $ 49,079 $ 37,977 $ 43,747 $ - $ 130,803 Gross profit 14,541 6,150 6,960 - 27,651 Income (loss) before income taxes 5,457 1,533 1,924 (1,269 ) 7,645

Subsequent Event

Subsequent Event	3 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	(10) Subsequent Event On October 28, 2015, the Company entered into an Amended and Restated Credit Agreement (the “A&R Credit Agreement”), which amended and restated in its entirety the Amended Credit Agreement (see Note 5). The A&R Credit Agreement eliminates the term loan commitment and increases the aggregate revolving commitment from $75,000 to an initial aggregate revolving commitment of $150,000, which may be further increased in accordance with the terms and conditions of the A&R Credit Agreement by an aggregate amount not to exceed $100,000.

Net Income Per Common Share (Ta

Net Income Per Common Share (Tables)	3 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding	Three months ended 2015 2014 Weighted average shares outstanding 28,983 28,618 Dilutive effect of stock options and restricted stock awards and units 409 560 Diluted weighted average shares outstanding 29,392 29,178

Debt (Tables)

Debt (Tables)	3 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of long-term debt	September 30, 2015 June 30, 2015 Revolving bank loans $ 47,500 $ 45,000 Term bank loans 59,500 62,000 Mortgage 3,108 3,157 110,108 110,157 Less current portion 197 10,197 $ 109,911 $ 99,960

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of summary of valuation of financial assets and liabilities	Fair Value Measurements at September 30, 2015 Using Quoted Prices Significant Significant Total Cash equivalents: Time deposits - $ 6,383 - $ 6,383 Investments: Time deposits - 2,392 - 2,392 Foreign currency contracts-assets (1) - 183 - 183 Foreign currency contracts-liabilities (2) - 438 - 438 Derivative liability for interest rate swap (3) - 487 - 487 Contingent consideration (4) - - $ 1,179 1,179 (1) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015. (2) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015. (3) $3 included in “Accrued expenses” and $484 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015. (4) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015. Fair Value Measurements at June 30, 2015 Using Quoted Prices Significant Significant Total Cash equivalents: Time deposits - $ 6,376 - $ 6,376 Investments: Time deposits - 3,416 - 3,416 Foreign currency contracts-assets (5) - 119 - 119 Foreign currency contracts-liabilities (6) - 767 - 767 Derivative liability for interest rate swap (7) - 338 - 338 Contingent consideration (8) - - $ 2,622 2,622 (5) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2015. (6) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2015. (7) $13 included in “Accrued expenses” and $325 included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2015. (8) $1,480 included in “Accrued expenses” and $1,142 included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2015.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Schedule of segment performance measures	Three Months Ended September 30, 2015 and 2014: Human Health Pharmaceutical Ingredients Performance Unallocated Corporate Consolidated Totals 2015 Net sales $ 57,481 $ 38,360 $ 37,659 $ - $ 133,500 Gross profit 20,309 6,114 8,158 - 34,581 Income (loss) before income taxes 10,503 2,099 3,544 (1,163 ) 14,983 2014 Net sales $ 49,079 $ 37,977 $ 43,747 $ - $ 130,803 Gross profit 14,541 6,150 6,960 - 27,651 Income (loss) before income taxes 5,457 1,533 1,924 (1,269 ) 7,645

Stock Based Compensation (Narra

Stock Based Compensation (Narrative) (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015	Dec. 06, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,467	$ 1,129
Restricted stock | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares	208		165
Restricted stock units, vesting period	3 years		3 years
Restricted stock | Non-employee directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares			12
Restricted stock units, vesting period			1 year
Restricted stock units | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares	46		67
Performance-vested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares	142		116
Upper limit of target grant, shares	248		203
Performance-vested restricted stock units, vesting percentage at the end of third year	100.00%		100.00%
Restricted stock and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,462	$ 1,103
Total unrecognized compensation cost	$ 12,531
2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of common stock that may be issued				5,250

Common Stock (Narrative) (Detai

Common Stock (Narrative) (Detail) - $ / shares shares in Thousands	Sep. 10, 2015	Oct. 02, 2015	May. 08, 2014
Dividends Payable [Line Items]
Dividends declared, per share amount	$ 0.06
Dividends declared, date of declaration	Sep. 10, 2015
Dividends declared, date of distribution	Oct. 2, 2015
Dividends declared, date of record	Sep. 21, 2015
Subsequent Event
Dividends Payable [Line Items]
Dividends paid, per share amount		$ 0.06
Stock repurchase program
Dividends Payable [Line Items]
Number of shares authorized to be repurchased			5,000

Net Income Per Common Share (Re

Net Income Per Common Share (Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) - shares shares in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Weighted average shares outstanding	28,983	28,618
Dilutive effect of stock options and restricted stock awards and units	409	560
Diluted weighted average shares outstanding	29,392	29,178

Debt (Summary of Long-term Debt

Debt (Summary of Long-term Debt) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Debt Instrument [Line Items]
Mortgage	$ 3,108	$ 3,157
Long-term debt including current portion	110,108	110,157
Less current portion	197	10,197
Long-term debt	109,911	99,960
Revolving bank loans
Debt Instrument [Line Items]
Long-term debt including current portion	47,500	45,000
Term bank loans
Debt Instrument [Line Items]
Long-term debt including current portion	$ 59,500	$ 62,000

Debt (Narrative) (Detail)

Debt (Narrative) (Detail) $ in Thousands	1 Months Ended			3 Months Ended
	Jun. 25, 2015USD ($)	Apr. 30, 2014USD ($)	Jun. 30, 2011USD ($)	Sep. 30, 2015USD ($)Installment	Jun. 30, 2015USD ($)
Debt Instrument [Line Items]
Term loan				$ 3,108	$ 3,157
Revolving bank loans | Amended Credit Agreement
Debt Instrument [Line Items]
Loans, maximum amount	$ 75,000	$ 60,000
Revolving loans, expiration date	Apr. 30, 2019	Apr. 30, 2019
Bank loans outstanding				$ 47,500
Lines of credit, variable rate basis				Eurodollar
Revolving bank loans | Amended Credit Agreement | Minimum
Debt Instrument [Line Items]
Lines of credit, interest rate				1.96%
Revolving bank loans | Amended Credit Agreement | Maximum
Debt Instrument [Line Items]
Lines of credit, interest rate				2.41%
Term bank loans | Amended Credit Agreement
Debt Instrument [Line Items]
Loans, maximum amount				$ 70,000
Bank loans outstanding		$ 70,000		$ 59,500
Lines of credit, variable rate basis				Eurodollar
Lines of credit, interest rate				2.08%
Term loans, number of installments | Installment				19
Mortgage payable
Debt Instrument [Line Items]
Term loan			$ 3,947
Mortgage payable interest rate				4.92%
Mortgage payable, amortization period			20 years
Open letter of credit | Amended Credit Agreement
Debt Instrument [Line Items]
Letters of credit				$ 21	$ 21

Commitments, Contingencies an26

Commitments, Contingencies and Other Matters (Narrative) (Detail) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 30, 2014USD ($)	Sep. 30, 2015USD ($)Entity	Jun. 30, 2009USD ($)	Jun. 30, 2015USD ($)
Pulvair Site Group
Commitments and Contingencies Disclosure [Line Items]
Loss contingency, damages sought		$ 1,700
Arsynco, Inc
Commitments and Contingencies Disclosure [Line Items]
Site contingency loss exposure not accrued, low estimate		16,500
Site contingency loss exposure not accrued, high estimate		18,300
Accrual for environmental loss contingencies		10,761		$ 11,079
BASF Corporation
Commitments and Contingencies Disclosure [Line Items]
Partial reimbursement of environmental remediation costs previously expensed			$ 550
Environmental remediation costs expensed in prior years			$ 1,200
Future remediation costs receivable		4,842		4,985
Subsidiary
Commitments and Contingencies Disclosure [Line Items]
Amount expected to be paid for product registrations and various task force groups		2,160
Amount accrued for product registrations and various task force groups		$ 0		0
Berry's Creek Study Area | Arsynco, Inc
Commitments and Contingencies Disclosure [Line Items]
Number of potentially responsible parties | Entity		150
Pack Pharmaceuticals Llc
Commitments and Contingencies Disclosure [Line Items]
Percentage of issued and outstanding membership interests acquired	100.00%
Purchase price, earn-out period	3 years
Purchase price, maximum earn-out amount	$ 15,000
Accrued contingent consideration		$ 808		$ 783

Fair Value Measurements (Summar

Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015		Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	$ 183	[1]	$ 119	[2]
Foreign currency contracts-liabilities	438	[3]	767	[4]
Derivative liability for interest rate swap	487	[5]	338	[6]
Contingent consideration	1,179	[7]	2,622	[8]
Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	6,383		6,376
Investments	$ 2,392		$ 3,416
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets		[1]		[2]
Foreign currency contracts-liabilities		[3]		[4]
Derivative liability for interest rate swap		[5]		[6]
Contingent consideration		[7]		[8]
Quoted Prices in Active Markets (Level 1) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Investments
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	$ 183	[1]	$ 119	[2]
Foreign currency contracts-liabilities	438	[3]	767	[4]
Derivative liability for interest rate swap	$ 487	[5]	$ 338	[6]
Contingent consideration		[7]		[8]
Significant Other Observable Inputs (Level 2) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 6,383		$ 6,376
Investments	$ 2,392		$ 3,416
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets		[1]		[2]
Foreign currency contracts-liabilities		[3]		[4]
Derivative liability for interest rate swap		[5]		[6]
Contingent consideration	$ 1,179	[7]	$ 2,622	[8]
Significant Unobservable Inputs (Level 3) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Investments
[1]	Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015.
[2]	Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2015.
[3]	Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015.
[4]	Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2015.
[5]	$3 included in "Accrued expenses" and $484 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015.
[6]	$13 included in "Accrued expenses" and $325 included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2015.
[7]	Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015.
[8]	$1,480 included in "Accrued expenses" and $1,142 included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2015.

Fair Value Measurements (Summ28

Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Parentheticals) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015		Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability for interest rate swap	$ 487	[1]	$ 338	[2]
Contingent consideration	1,179	[3]	2,622	[4]
Accrued expenses
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability for interest rate swap	3		13
Contingent consideration			1,480
Long-term liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability for interest rate swap	$ 484		325
Contingent consideration			$ 1,142
[1]	$3 included in "Accrued expenses" and $484 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015.
[2]	$13 included in "Accrued expenses" and $325 included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2015.
[3]	Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2015.
[4]	$1,480 included in "Accrued expenses" and $1,142 included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2015.

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Apr. 30, 2014	Mar. 31, 2011	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015
Rising Pharmaceuticals Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration at fair value					$ 1,480
PACK Pharmaceuticals, LLC
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration at fair value			$ 808		783
France Company
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration at fair value			371		$ 359
Foreign currency contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount			53,203
Unrealized losses on hedging activities			(251)	$ (806)
Interest rate swap | Cash flow hedging
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized loss recorded in accumulated other comprehensive income			(487)
Interest rate swap | Cash flow hedging | April 30, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	$ 25,750		29,000
Derivative, interest rate	1.63%
Derivative, expiration date	Apr. 30, 2019
Interest rate swap | Cash flow hedging | December 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount		$ 20,000	$ 750
Derivative, interest rate		1.91%
Derivative, expiration date		Dec. 31, 2015

Segment Information (Summary of

Segment Information (Summary of Segment Perfomance Measures by Segment) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Net sales	$ 133,500	$ 130,803
Gross profit	34,581	27,651
Income (loss) before income taxes	14,983	7,645
Operating Segments | Human Health
Segment Reporting Information [Line Items]
Net sales	57,481	49,079
Gross profit	20,309	14,541
Income (loss) before income taxes	10,503	5,457
Operating Segments | Pharmaceutical Ingredients
Segment Reporting Information [Line Items]
Net sales	38,360	37,977
Gross profit	6,114	6,150
Income (loss) before income taxes	2,099	1,533
Operating Segments | Performance Chemicals
Segment Reporting Information [Line Items]
Net sales	37,659	43,747
Gross profit	8,158	6,960
Income (loss) before income taxes	$ 3,544	$ 1,924
Unallocated Corporate
Segment Reporting Information [Line Items]
Net sales
Gross profit
Income (loss) before income taxes	$ (1,163)	$ (1,269)

Segment Information (Narrative)

Segment Information (Narrative) (Detail)	3 Months Ended
	Sep. 30, 2015Segment
Segment Reporting [Abstract]
Number of operating segments	3

Subsequent Event (Narrative) (D

Subsequent Event (Narrative) (Detail) - Revolving bank loans - A&R Credit Agreement - USD ($) $ in Thousands	1 Months Ended
	Oct. 28, 2015	Jun. 25, 2015	Apr. 30, 2014
Subsequent Event [Line Items]
Aggregate revolving commitment		$ 75,000	$ 60,000
Subsequent Event
Subsequent Event [Line Items]
Aggregate revolving commitment	$ 150,000
Aggregate amount increase	$ 100,000